Form 4: Femasys CEO Awarded Stock Options

Femasys CEO Kathy Lee-Sepsick was granted stock options for a total of 442,902 shares, vesting over three and four years.

Summary

• Kathy Lee-Sepsick, CEO of Femasys Inc., was granted stock options on January 29, 2025.
• The options are for a total of 442,902 shares of common stock.
• The exercise price for all options is $1.17 per share.
• Some options for 59,849 shares vest over three years, while others for 262,700 shares vest over four years, both starting January 29, 2025.
• An additional 120,353 options vest immediately on January 29, 2025.
• All options expire on January 29, 2035.
• Vesting is contingent upon continued employment with Femasys or a subsidiary.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally positive for aligning management and shareholder interests. The vesting schedule is also a positive sign of long-term commitment.

Positives

• The granting of stock options aligns the CEO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.
• The options provide an incentive for the CEO to increase the company's value.

Risks

• The value of the options is dependent on the future performance of Femasys stock.
• If the stock price does not increase above the exercise price, the options will have no value.
• The vesting is contingent on continued employment, which could be a risk if the CEO leaves the company.

Future Outlook

The stock options are designed to incentivize the CEO to drive long-term value creation for the company.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology and medical device industries, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation in the biotech industry.
• The vesting schedules of three and four years are typical for such grants, encouraging long-term commitment.
• The exercise price of $1.17 is a common practice, usually set at or near the current market price at the time of the grant.
• Companies like Intuitive Surgical and Medtronic also use stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the CEO's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, executive compensation, Femasys, CEO, Kathy Lee-Sepsick, vesting, equity